Sign in
Taking people in United StatesPhase 2

Abemaciclib compared with placebo for newly diagnosed grade 3 meningioma

Tests abemaciclib against placebo in adults newly diagnosed with grade 3 meningioma.

Key facts

Who runs it
Nader Sanai
Where
Phoenix, United StatesSee the site
Trial code
Registry title
Abemaciclib in Newly Diagnosed Meningioma Patients
Status
Recruiting
Phase
Phase 2
People taking part
72 people, planned
Started
24 Mar 2025
Expected to end
Sept 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Abemaciclib
  • Placebo
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a newly diagnosed grade 3 meningioma, a brain tumor, whose tumor tissue tests positive for RB. They get abemaciclib or a placebo after standard radiation therapy.

Age
18 years and older
Sex
All sexes
Disease stage
Newly diagnosed WHO Grade 3 meningioma inside the skull, or a lower grade meningioma that has newly changed to Grade 3. People must be up and about at least half the day (ECOG 2 or less).
Earlier treatment
People must plan to have, or have had, standard radiation therapy for the Grade 3 meningioma. No other treatment for it before, except surgery or biopsy. If you had a lower grade meningioma before, only surgery or biopsy, and no radiation. No prior CDK4/6 inhibitor.
Biomarker or test result
Tumor tissue from surgery must test positive for RB (RB-proficient).

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Another cancer still being treated
  • Active or uncontrolled serious infection, including known HIV, HBV or HCV
  • Liver disease such as cirrhosis or active hepatitis
  • Allergy to parts of abemaciclib

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Participants with newly diagnosed intracranial WHO Grade 3 meningioma; or,
  • Participants with previous lower grade meningioma and histopathologically confirmed newly transformation to Grade 3
  • Plan to receive or have received upfront standard of care radiation therapy (RT) for the newly diagnosed WHO Grade 3 meningioma
  • No prior treatment for Grade 3 meningioma other than surgical resection or biopsy and upfront RT. If previously diagnosed with a lower grade meningioma, no prior treatment other than surgical resection or biopsy and no prior RT
  • Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable)
  • Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative[s], and assent, if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally document and witnessed, ideally via an independent trusted witness. Participant must be willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures
  • Age ≥18 years at time of consent
  • Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Ability to swallow oral medications
  • Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):; Adequate Bone Marrow Function: absolute neutrophil count ≥1,500/mcL, platelets ≥100,000/mcL, and hemoglobin ≥8.0 g/dL (individual may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must no begin earlier than the day after any erythrocyte transfusion); Adequate Hepatic Function: total bilirubin ≤1.5x ULN (individuals with Gilbert's syndrome with a total bilirubin ≤2.0x ULN and direct bilirubin within normal limits are permitted), AST/SGOT ≤3x ULN, and ALT/SGPT ≤3x ULN
  • Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause
  • For females of reproductive potential: use of highly effective contraception during study participation and for an additional 3 weeks after the end of treatment administration
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 3 weeks after the end of treatment administration

Who cannot take part

  • Prior therapy with any CDK4/6 inhibitor. Prior therapy is defined as therapeutic dosing
  • Treatment with another investigational drug within 5 half-lives of the investigational product
  • Prior history of cancer with ongoing treatment of disease
  • Known allergic reactions to components of the abemaciclib
  • Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1
  • Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis
  • Known active systemic bacterial infection (requiring IV antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known HIV positivity or with known HBV or HCV). Screening is not required for enrollment
  • Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study
  • Pregnancy or breastfeeding

Where in United States

  • St. Joseph's Hospital and Medical CenterPhoenix, United StatesContact: Phase 0 NavigatorTaking people

About the trial

What the trial wants to find out

This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.

Read full original descriptionShow less

Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy.

This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.

The 2 groups in the trial

  • Active Treatment (Abemaciclib)Treatment being tested

    Administered twice daily on days 1-28 of each 28-day cycle.

    Treatment: Abemaciclib

  • PlaceboPlacebo, for comparison

    Administered twice daily on days 1-28 of each 28-day cycle.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
Plain-language title
Abemaciclib compared with placebo for newly diagnosed grade 3 meningiomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 March 2026